EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chronic Inflammation’s Transformation to Cancer: A Nanotherapeutic Paradigm

Sayed Sartaj Sohrab iD, Riya Raj, Amka Nagar, Susan Hawthorne iD, Ana Cláudia Paiva-Santos iD, Mohammad Amjad Kamal iD, Mai M El-Daly iD, Esam I Azhar iD, Ankur Sharma

Molecules · 29.05.2023 · 28 (11) · 4413

DOI: 10.3390/molecules28114413 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 29.05.2023. Verfasst von Sayed Sartaj Sohrab und 8 weiteren Autor:innen. Beteiligte Einrichtung: Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Hauptthemen laut MEDLINE: Inflammation, Neoplasms. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This review work was funded by Institutional Fund Projects under grant no. (IFPIP:504-141-1443). The authors gratefully acknowledge the technical and financial…, Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi, Institutional Fund Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The body’s normal immune response against any invading pathogen that causes infection in the body results in inflammation. The sudden transformation in inflammation leads to the rise of inflammatory diseases such as chronic inflammatory bowel disease, autoimmune disorders, and colorectal cancer (different types of cancer develop at the site of chronic infection and inflammation). Inflammation results in two ways: short-term inflammation i.e., non-specific, involves the action of various immune cells; the other results in long-term reactions lasting for months or years. It is specific and causes angiogenesis, fibrosis, tissue destruction, and cancer progression at the site of inflammation. Cancer progression relies on the interaction between the host microenvironment and tumor cells along with the inflammatory responses, fibroblast, and vascular cells. The two pathways that have been identified connecting inflammation and cancer are the extrinsic and intrinsic pathways. Both have their own specific role in linking inflammation to cancer, involving various transcription factors such as Nuclear factor kappa B, Activator of transcription, Single transducer, and Hypoxia-inducible factor, which in turn regulates the inflammatory responses via Soluble mediators cytokines (such as Interleukin-6, Hematopoietin-1/Erythropoietin, and tumor necrosis factor), chemokines (such as Cyclooxygenase-2, C-X-C Motif chemokines ligand-8, and IL-8), inflammatory cells, cellular components (such as suppressor cells derived from myeloid, tumor-associated macrophage, and acidophils), and promotes tumorigenesis. The treatment of these chronic inflammatory diseases is challenging and needs early detection and diagnosis. Nanotechnology is a booming field nowadays for its rapid action and easy penetration inside the infected destined cells. Nanoparticles are widely classified into different categories based on their different factors and properties such as size, shape, cytotoxicity, and others. Nanoparticles emerged as excellent with highly progressive medical inventions to cure diseases such as cancer, inflammatory diseases, and others. Nanoparticles have shown higher binding capacity with the biomolecules in inflammation reduction and lowers the oxidative stress inside tissue/cells. In this review, we have overall discussed inflammatory pathways that link inflammation to cancer, major inflammatory diseases, and the potent action of nanoparticles in chronic inflammation-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammationNeoplasmsHumansCytokinesNF-kappa BChemokinesTumor Microenvironment

Stichwörter der Autor:innen

cancerdrug deliveryinflammationinflammatory pathwaysnanoparticles

Substanzen

CytokinesNF-kappa BChemokines

Autor:innen und Institutionen

  • Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Department of Biochemistry, Bangalore University, Banglore 560056, India.
  • Department of Life Science, School of Basic Science and Research, Sharda University, Greater Noida 201310, India.
  • School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine BT52 1SA, UK.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy of University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal.

ORCID-Profile: Sayed Sartaj Sohrab, Susan Hawthorne, Ana Cláudia Paiva-Santos, Mohammad Amjad Kamal, Mai M El-Daly, Esam I Azhar

Förderung

  • This review work was funded by Institutional Fund Projects under grant no. (IFPIP:504-141-1443). The authors gratefully acknowledge the technical and financial…
  • Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi
  • Institutional Fund Projects

Zitieren

APA

Sohrab, S. S., Raj, R., Nagar, A., Hawthorne, S., Paiva-Santos, A. C., Kamal, M. A., El-Daly, M. M., Azhar, E. I., & Sharma, A. (2023). Chronic Inflammation’s Transformation to Cancer: A Nanotherapeutic Paradigm. Molecules, 28(11), 4413. https://doi.org/10.3390/molecules28114413

Vancouver

Sohrab SS, Raj R, Nagar A, Hawthorne S, Paiva-Santos AC, Kamal MA, et al. Chronic Inflammation’s Transformation to Cancer: A Nanotherapeutic Paradigm. Molecules. 2023;28(11):4413. doi:10.3390/molecules28114413

BibTeX
@article{Sohrab2023,
  author = {Sohrab, Sayed Sartaj and Raj, Riya and Nagar, Amka and Hawthorne, Susan and Paiva-Santos, Ana Cláudia and Kamal, Mohammad Amjad and El-Daly, Mai M and Azhar, Esam I and Sharma, Ankur},
  title = {Chronic Inflammation’s Transformation to Cancer: A Nanotherapeutic Paradigm},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {11},
  pages = {4413},
  doi = {10.3390/molecules28114413}
}
Kostenlos starten →